[CAS NO. 1002789-86-7]  TZ9

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1002789-86-7]

Catalog
HY-18643
Brand
MCE
CAS
1002789-86-7

DESCRIPTION [1002789-86-7]

Overview

MDL-
Molecular Weight366.33
Molecular FormulaC17H14N6O4
SMILESO=C(OCC1=NC(N)=NC(NC2=CC=CC=C2)=N1)C3=CC=C([N+]([O-])=O)C=C3

For research use only. We do not sell to patients.


Summary

TZ9 is a selective Rad6 inhibitor. TZ9 inhibits Rad6B -induced histone H2A ubiquitination, downregulates intracellular β-catenin , induces G2-M arrest and apoptosis , and inhibits the proliferation and migration of metastatic human breast cancer cells [1] .


In Vitro

TZ9 (Rad6B SMI #9) (0.5-100 µM; 72 h) inhibits MDA-MB-231 cell proliferation and migration [1] .
TZ9 (0.1-5 µM; 24-72 h) delays cell-cycle progression in MDA-MB-231 cells [1] .
TZ9 (5 µM; 8-48 h) induces apoptosis in MDA-MB-231 cells [1] .
TZ9 (0.5, 1, 2.5, 5 µM; 24 h) inhibits H2A ubiquitination and downregulates levels of PCNA and β-catenin protein in MDA-MB-231 cells [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay [1]

Cell Line: MDA-MB-231 cells
Concentration: 0.5-100 µM
Incubation Time: 72 h
Result: Inhibited MDA-MB-231 cell proliferation with IC 50 ~6µM.

Apoptosis Analysis [1]

Cell Line: MDA-MB-231 cells
Concentration: 5 µM
Incubation Time: 8-48 h
Result: Induced cells apoptosis.

Cell Cycle Analysis [1]

Cell Line: MDA-MB-231 cells
Concentration: 0.1-5 µM
Incubation Time: 24-72 h
Result: Increased the proportion of G2-M-arrested cells by 2-fold and was accompanied by a proportional decrease in S-phase cells when at 24 h.
Significantly increased the percentage of cells with cytoplasmic/nuclear cyclin B1 staining.

Western Blot Analysis [1]

Cell Line: MDA-MB-231 cells
Concentration: 0.5, 1, 2.5, 5 µM
Incubation Time: 24 h
Result: Inhibited H2A ubiquitination, decreased PCNA and β-catenin protein levels.

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 40 mg/mL ( 109.19 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.7298 mL 13.6489 mL 27.2978 mL
5 mM 0.5460 mL 2.7298 mL 5.4596 mL
10 mM 0.2730 mL 1.3649 mL 2.7298 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 2.5 mg/mL (6.82 mM); Clear solution

  • 2.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 2.08 mg/mL (5.68 mM); Clear solution

* All of the co-solvents are available by MCE.